Better Buy: Novo Nordisk vs. AstraZeneca
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...
Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'
Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...
Seeking Alpha6d
Novo Nordisk seeks to block compounded Victoza
Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...
Novo Nordisk, Valo Health expand drug discovery deal
Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...
Nasdaq5d
Better Buy: Novo Nordisk vs. AstraZeneca
Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...